Search Results - "Abegesah, Aburough"

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study

    Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study by He, Jimmy Zhijian, Duval, Vincent, Jauslin, Petra, Gonçalves, Antonio, Abegesah, Aburough, Fan, Chunling, Lim, KyoungSoo, Song, Xuyang, Chen, Cecil, Shi, Xiaojin, Mann, Helen, Krug, Lee, Ren, Song, Phipps, Alex, Gibbs, Megan, Zhou, Diansong

    Published in Clinical pharmacology and therapeutics (01-12-2023)
    “…Blockade of CTLA-4 by tremelimumab combined with anti-PD-L1 durvalumab and chemotherapy provided increased antitumor activity and long-term survival benefits…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma

    Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma by Lim, KyoungSoo, Abegesah, Aburough, Fan, Chunling, He, Jimmy Zhijian, Song, Xuyang, Chen, Cecil, Negro, Alejandra, Makowsky, Mallory, Gupta, Charu, Ren, Song, Phipps, Alex, Gibbs, Megan, Zhou, Diansong

    Published in Journal of clinical pharmacology (01-11-2023)
    “…A novel single-dose regimen of 300 mg tremelimumab in combination with durvalumab (STRIDE) has demonstrated a favorable benefit-risk profile in the phase 1/2…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: